In contrast, chemoimmunotherapy (CIT) demonstrated superiority in OS over platinum-based chemotherapy as the first-line treatment for NSCLC, irrespective of PD-L1 expression status (10–13). This evidence concerns the gene CD274 and non-small cell lung carcinoma.